Effect of Diphenhydramine Compound in Covid-19

Clinical Trial on Diphenhydramine Compound in Covid-19 Treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200504047298N3

Enrollment

120

Registered

2020-09-09

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. virus identified’ is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.

Interventions

Intervention 1: Intervention group:According to the inclusion criteria and in addition to the treatments recommended in the national guideline, all patients with Quid-19, who were divided into three g

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Confirmed Covid-19 Infection Age between 18_70 years old

Exclusion criteria

Exclusion criteria: Cardiovascular disease non confirmed patients Addicted patient

Design outcomes

Primary

Measure	Time frame
Change of involment of lung in HRCT(High-resolution computed tomography). Timepoint: Day 0 and 7 Days later. Method of measurement: HRCT(High-resolution computed tomography).;Change of viral load in Real Time PCR. Timepoint: Day 0 and 7 days later. Method of measurement: Real Time PCR nasopharengeal soap.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Siami

Karaj University of Medical Sciences

z.siami@abzums.ac.ir+98 21 4602 2136

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026